+122.4%
GLW vs MRNA
+485.7%
-363.3%
-51.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.0% | +5.4% | -3.4% | +2.0% |
| 7D | +7.8% | -1.1% | +8.9% | +7.8% |
| 30D | -0.4% | +126.1% | -126.6% | +0.8% |
| 3M | -5.6% | +190.0% | -195.6% | -8.8% |
| 6M | +26.7% | +157.2% | -130.5% | +23.2% |
| YTD | +91.0% | +388.2% | -297.2% | +69.0% |
| 1Y | +122.4% | +467.0% | -344.6% | +93.0% |
| All | +122.4% | +485.7% | -363.3% | +93.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling